Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 4375418, 10 pages
http://dx.doi.org/10.1155/2016/4375418
Research Article

Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target

1Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Center of Molecular Medicine (CIMMBA), University of Florence, Florence, Italy
2Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
3Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy

Received 12 July 2016; Revised 19 September 2016; Accepted 9 October 2016

Academic Editor: Mohammad T. Elnakish

Copyright © 2016 Maria Elena Manni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Nediani, L. Raimondi, E. Borchi, and E. Cerbai, “Nitric oxide/reactive oxygen species generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications,” Antioxidants and Redox Signaling, vol. 14, no. 2, pp. 289–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, and F. Di Lisa, “Monoamine oxidases as sources of oxidants in the heart,” Journal of Molecular and Cellular Cardiology, vol. 73, pp. 34–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Kaludercic, A. Carpi, R. Menabò, F. Di Lisa, and N. Paolocci, “Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1813, no. 7, pp. 1323–1332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Shih, “Monoamine oxidases: from tissue homogenates to transgenic mice,” Neurochemical Research, vol. 32, no. 10, pp. 1757–1761, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. B. H. Youdim, D. Edmondson, and K. F. Tipton, “The therapeutic potential of monoamine oxidase inhibitors,” Nature Reviews Neuroscience, vol. 7, no. 4, pp. 295–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. D. Berry, A. V. Juorio, and I. A. Paterson, “The functional role of monoamine oxidases A and B in the mammalian central nervous system,” Progress in Neurobiology, vol. 42, no. 3, pp. 375–391, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. M. Finberg, “Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release,” Pharmacology and Therapeutics, vol. 143, no. 2, pp. 133–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Naoi, P. Riederer, and W. Maruyama, “Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression,” Journal of Neural Transmission, vol. 123, no. 2, pp. 91–106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Bianchi, D. R. Pimentel, M. P. Murphy, W. S. Colucci, and A. Parini, “A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation,” The FASEB Journal, vol. 19, no. 6, pp. 641–643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Villeneuve, A. Caudrillier, C. Ordener, N. Pizzinat, A. Parini, and J. Mialet-Perez, “Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 297, no. 2, pp. H821–H828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Sabri, H. H. Hughie, and P. A. Lucchesi, “Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes,” Antioxidants & Redox Signaling, vol. 5, no. 6, pp. 731–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Bianchi, O. Kunduzova, E. Masini et al., “Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury,” Circulation, vol. 112, no. 21, pp. 3297–3305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Fischer, J. Thomas, J. Kamp et al., “5-Hydroxylryptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction,” Biochemical Journal, vol. 311, no. 2, pp. 575–583, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Mialet-Perez, P. Bianchi, O. Kunduzova, and A. Parini, “New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart,” Journal of Neural Transmission, vol. 114, no. 6, pp. 823–827, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Kaludercic, E. Takimoto, T. Nagayama et al., “Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload,” Circulation Research, vol. 106, no. 1, pp. 193–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, and M. Giorgio, “Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase,” Basic Research in Cardiology, vol. 104, no. 2, pp. 131–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Carpi, R. Menabò, N. Kaludercic, P. Pelicci, F. Di Lisa, and M. Giorgio, “The cardioprotective effects elicited by p66Shc ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury,” Biochimica et Biophysica Acta—Bioenergetics, vol. 1787, no. 7, pp. 774–780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Villeneuve, C. Guilbeau-Frugier, P. Sicard et al., “P53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-a upregulation: role in chronic left ventricular dysfunction in mice,” Antioxidants and Redox Signaling, vol. 18, no. 1, pp. 5–18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Umbarkar, S. Sarojini Singh, S. Arkat, S. L. Bodhankar, S. Lohidasan, and S. L. Sitasawad, “Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy,” Free Radical Biology and Medicine, vol. 87, pp. 263–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Kaludercic, A. Carpi, T. Nagayama et al., “Monoamine Oxidase b prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts,” Antioxidants and Redox Signaling, vol. 20, no. 2, pp. 267–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Borchi, V. Bargelli, F. Stillitano et al., “Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1802, no. 3, pp. 331–338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. B. A. Stanley, V. Sivakumaran, S. Shi et al., “Thioredoxin reductase-2 is essential for keeping low levels of H2O2 emission from isolated heart mitochondria,” Journal of Biological Chemistry, vol. 286, no. 38, pp. 33669–33677, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. G. R. Budas, M.-H. Disatnik, and D. Mochly-Rosen, “Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target?” Trends in Cardiovascular Medicine, vol. 19, no. 5, pp. 158–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Malátková, E. Maser, and V. Wsól, “Human carbonyl reductases,” Current Drug Metabolism, vol. 11, no. 8, pp. 639–658, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-H. Chen, G. R. Budas, E. N. Churchill, M.-H. Disatnik, T. D. Hurley, and D. Mochly-Rosen, “Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart,” Science, vol. 321, no. 5895, pp. 1493–1495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. N. Churchill, M.-H. Disatnik, and D. Mochly-Rosen, “Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of εPKC and activation of aldehyde dehydrogenase 2,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 2, pp. 278–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Ma, R. Guo, L. Yu, Y. Zhang, and J. Ren, “Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde,” European Heart Journal, vol. 32, no. 8, pp. 1025–1038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. E. Manni, M. Zazzeri, C. Musilli, E. Bigagli, M. Lodovici, and L. Raimondi, “Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: implications in heart failure,” European Journal of Pharmacology, vol. 718, no. 1–3, pp. 271–276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Santin, P. Sicard, Y. Yücel et al., “Role and mechanisms of action of aldehydes produced by monoamine oxidase A in cardiomyocyte death and heart failure,” Cardiovascular Research, vol. 11, p. S23, 2016. View at Google Scholar
  30. M. Guglin and H. Khan, “Pulmonary hypertension in heart failure,” Journal of Cardiac Failure, vol. 16, no. 6, pp. 461–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Brieke and D. DeNofrio, “Right ventricular dysfunction in chronic dilated cardiomyopathy and heart failure,” Coronary Artery Disease, vol. 16, no. 1, pp. 5–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. H. Drazner, M. Velez-Martinez, C. R. Ayers et al., “Relationship of right- to left-sided ventricular filling pressures in advanced heart failure. Insights from the escape trial,” Circulation: Heart Failure, vol. 6, no. 2, pp. 264–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Raimondi, G. Banchelli, L. Sgromo et al., “Hydrogen peroxide generation by monoamine oxidases in rat white adipocytes: role on cAMP production,” European Journal of Pharmacology, vol. 395, no. 3, pp. 177–182, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984. View at Publisher · View at Google Scholar
  35. P. Wenzel, U. Hink, M. Oelze et al., “Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance,” The Journal of Biological Chemistry, vol. 282, no. 1, pp. 792–799, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Correa-Salde and I. Albesa, “Reactive oxidant species and oxidation of protein and heamoglobin as biomarkers of susceptibility to stress caused by chloramphenicol,” Biomedicine and Pharmacotherapy, vol. 63, no. 2, pp. 100–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R. R. Nigmatullina, V. V. Kirillova, R. K. Jourjikiya et al., “Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment,” Cardiology, vol. 113, no. 4, pp. 277–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. W. Kong, N. Bodyak, P. Yue et al., “Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats,” Physiological Genomics, vol. 21, pp. 34–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Roselló-Lletí, J. Alonso, R. Cortés et al., “Cardiac protein changes in ischaemic and dilated cardiomyopathy: a proteomic study of human left ventricular tissue,” Journal of Cellular and Molecular Medicine, vol. 16, no. 10, pp. 2471–2486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Li, R. Rong, S. Zhao et al., “Proteomic analysis of metabolic, cytoskeletal and stress response proteins in human heart failure,” Journal of Cellular and Molecular Medicine, vol. 16, no. 1, pp. 59–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Schömig, “Catecholamines in myocardial ischemia. Systemic and cardiac release,” Circulation, vol. 82, no. 3, pp. II13–II22, 1990. View at Google Scholar · View at Scopus
  42. Y. Shimizu, S. Minatoguchi, K. Hashimoto et al., “The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts,” Journal of the American College of Cardiology, vol. 40, no. 7, pp. 1347–1355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Shih and K. Chen, “Regulation of MAO-A and MAO-B gene expression,” Current Medicinal Chemistry, vol. 11, no. 15, pp. 1995–2005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Djordjevic, N. Jasnic, P. Vujovic et al., “Distinct and combined effects of acute immobilization and chronic isolation stress on MAO activity and antioxidative protection in the heart of normotensive and spontaneously hypertensive rats,” Journal of Animal Physiology and Animal Nutrition, vol. 96, no. 1, pp. 58–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Littlejohns, K. Heesom, G. D. Angelini, and M.-S. Suleiman, “The effect of disease on human cardiac protein expression profiles in paired samples from right and left ventricles,” Clinical Proteomics, vol. 11, article 34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Canton, S. Menazza, F. L. Sheeran, P. Polverino De Laureto, F. Di Lisa, and S. Pepe, “Oxidation of myofibrillar proteins in human heart failure,” Journal of the American College of Cardiology, vol. 57, no. 3, pp. 300–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. R. Powell, E. M. Gurzenda, and S. E. Wahezi, “Actin is oxidized during myocardial ischemia,” Free Radical Biology and Medicine, vol. 30, no. 10, pp. 1171–1176, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Nediani, E. Borchi, C. Giordano et al., “NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 4, pp. 826–834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. V. DeMarco, A. Whaley-Connell, J. Sowers, J. Habibi, and K. Dellsperger, “Contribution of oxidative stress to pulmonary arterial hypertension,” World Journal of Cardiology, vol. 2, no. 10, pp. 316–324, 2010. View at Publisher · View at Google Scholar
  50. N. Voelkel, R. Quaife, L. Leinwand et al., “National Heart, Lung and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure Right ventricular function and failure. Report of a National Heart, Lung and Blood Institute Working Group on cellular and molecular mechanisms of right heart failure,” Circulation, vol. 114, pp. 1883–1891, 2006. View at Publisher · View at Google Scholar
  51. E. Roselló-Lletí, E. Tarazón, M. G. Barderas et al., “ATP synthase subunit alpha and LV mass in ischaemic human hearts,” Journal of Cellular and Molecular Medicine, vol. 19, no. 2, pp. 442–451, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Sebastiani, C. Giordano, C. Nediani et al., “Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies,” Journal of the American College of Cardiology, vol. 50, no. 14, pp. 1362–1369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. E. J. Anderson, J. T. Efird, S. W. Davies et al., “Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation,” Journal of the American Heart Association, vol. 3, no. 1, article e000713, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Petrak, J. Pospisilova, M. Sedinova et al., “Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets—monoamine oxidase A and transglutaminase 2,” Proteome Science, vol. 9, pp. 69–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Octavia, H. P. Brunner-La Rocca, and A. L. Moens, “NADPH oxidase-dependent oxidative stress in the failing heart: from pathogenic roles to therapeutic approach,” Free Radical Biology and Medicine, vol. 52, no. 2, pp. 291–297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. I. Casas, V. T.-V. Dao, A. Daiber et al., “Reactive oxygen-related diseases: therapeutic targets and emerging clinical indications,” Antioxidants and Redox Signaling, vol. 23, no. 14, pp. 1171–1185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. D. B. Marin, L. M. Bierer, B. A. Lawlor et al., “L-deprenyl and physostigmine for the treatment of Alzheimer's disease,” Psychiatry Research, vol. 58, no. 3, pp. 181–189, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. S. N. Deftereos, E. Dodou, C. Andronis, and A. Persidis, “From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors,” Expert Review of Clinical Pharmacology, vol. 5, no. 4, pp. 413–425, 2012. View at Publisher · View at Google Scholar · View at Scopus